Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Trials (London, England)|October 4, 2014
A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challengesY H Joshua Chen, Richard Gesser, Alain Luxembourg
Surgical Infections|April 17, 2003
Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infectionsJose Tellado, Gail L Woods, Richard Gesser, et al.
American Journal of Surgery|August 19, 2007
Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patientsAlbert E Yellin, Jeffrey Johnson, Iliana Higareda, et al.
Clinical and Vaccine Immunology : CVI|March 19, 2010
Multiplexed serologic assay for nine anogenital human papillomavirus typesDavid Opalka, Katie Matys, Paul Bojczuk, et al.
International Journal of Antimicrobial Agents|October 24, 2008
Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infectionAdriano Arguedas, Jaime Cespedes, Francesc Aseni Botet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2002
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter studyDonald R Graham, Christopher Lucasti, Osvaldo Malafaia, et al.
Vaccine|March 26, 2016
Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trialGuy de Bruyn, Jamshid Saleh, David Workman, et al.
The Lancet. Infectious Diseases|September 18, 2020
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trialGuy de Bruyn, David L Gordon, Theodore Steiner, et al.
The New England Journal of Medicine|February 19, 2015
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in womenElmar A Joura, Anna R Giuliano, Ole-Erik Iversen, et al.
Pageof 1